Dr. David A Russler-Germain, a lymphoma clinician scientist from Washington University, shares insights on groundbreaking lymphoma and CLL research from ASH 2024. They delve into the promising results of the TRIANGLE trial for mantle cell lymphoma, highlighting significant survival gains with ibrutinib. The discussion also covers the efficacy of Tafasitamab in follicular lymphoma and the impressive response rates for Longcast Tuximab Tessarine. Additionally, they evaluate new treatment strategies for CLL and the implications for patient care.